SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?


To: Hong-Lee Yu who wrote (731)9/10/1998 7:27:00 PM
From: Hong-Lee Yu  Read Replies (1) | Respond to of 1686
 
Another upgrade from CIBC.

Note that Matt Geller estimated BGEN will earn 51C in Q3. 1.80 for the year (52C for Q4 ?). He has 58 target price for the year (reach today).

Also he mentioned that there are 37000 Avonex patients in USA, 3000 increase from Q2. If Europe adds another 2000 patients, we should see Avonex revenue in 100M range. I couldn't understand his logic why Q4 is only 1C better than Q3.